Skip to content
2000
image of Nucleolin as a Crucial Player in Head and Neck Cancer: Diagnostic and Therapeutic Perspectives

Abstract

Head and Neck Cancer (HNC) encompasses a diverse group of malignancies arising in the oral cavity, pharynx, larynx, and related structures. It represents a significant global health bur- den due to its high incidence, aggressive progression, and strong associations with environmental and viral risk factors like tobacco use and HPV infection. HNC, particularly squamous cell carcinoma, ranks as the seventh most common cancer worldwide. Despite the established role of these risk factors, the molecular mechanisms driving disease progression remain underexplored, especially in the context of specific biomarkers like Nucleolin (NCL). Nucleolin, a multifunctional protein, is pivotal in cancer progression, regulating cell proliferation, angiogenesis, and apoptosis. Data from The Cancer Genome Atlas (TCGA) reveal significant overexpression of NCL in HNC, particularly in advanced stages, correlating with poor prognosis and reduced patient survival. These findings highlight its potential as a diagnostic and therapeutic target. This review provides a fresh perspective on the underexplored potential of NCL as a therapeutic target in HPV-induced HNC and oral cancer. Emerging approaches, such as the AS1411 aptamer and F3 peptide, offer promising avenues for targeting NCL, paving the way for more effective, personalized cancer therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096370250250513115130
2025-07-02
2025-07-20

  • From This Site

    /content/journals/ccdt/10.2174/0115680096370250250513115130
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  2. Chauhan R. Trivedi V. Rani R. Singh U. A study of head and neck cancer patients with reference to tobacco use, gender, and subsite distribution. South Asian J. Cancer 2022 11 1 046 051 10.1055/s‑0041‑1740601 35833037
    [Google Scholar]
  3. Nam I-C. Park J-O. Kim C-S. Park S.J. Lee D-H. Kim H-B. Han K. Joo Y-H. Association of smoking status, duration and amount with the risk of head and neck cancer subtypes: A national population-based study. Am. J. Cancer Res. 2022 12 10 4815 4824 36381316
    [Google Scholar]
  4. Mody M.D. Rocco J.W. Yom S.S. Haddad R.I. Saba N.F. Head and neck cancer. Lancet 2021 398 2289 2299 10.1016/S0140‑6736(21)01550‑6
    [Google Scholar]
  5. Bravi F. Bosetti C. Filomeno M. Levi F. Garavello W. Galimberti S. Negri E. La Vecchia C. Foods, nutrients and the risk of oral and pharyngeal cancer. Br. J. Cancer 2013 109 11 2904 2910 10.1038/bjc.2013.667 24149181
    [Google Scholar]
  6. Warnakulasuriya S. Chen T.H.H. Areca nut and oral cancer: Evidence from studies conducted in humans. J. Dent. Res. 2022 101 10 1139 1146 10.1177/00220345221092751 35459408
    [Google Scholar]
  7. Lechner M. Liu J. Masterson L. Fenton T.R. HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management. Nat. Rev. Clin. Oncol. 2022 19 5 306 327 10.1038/s41571‑022‑00603‑7 35105976
    [Google Scholar]
  8. Cerasuolo A. Buonaguro L. Buonaguro F.M. Tornesello M.L. The role of RNA splicing factors in cancer: Regulation of viral and human gene expression in human papillomavirus-related cervical cancer. Front. Cell Dev. Biol. 2020 8 474 10.3389/fcell.2020.00474 32596243
    [Google Scholar]
  9. Weeks S.E. Metge B.J. Samant R.S. The nucleolus: A central response hub for the stressors that drive cancer progression. Cell. Mol. Life Sci. 2019 76 22 4511 4524 10.1007/s00018‑019‑03231‑0 31338556
    [Google Scholar]
  10. Tajrishi M.M. Tuteja R. Tuteja N. Nucleolin. Commun. Integr. Biol. 2011 4 3 267 275 10.4161/cib.4.3.14884 21980556
    [Google Scholar]
  11. Scott D.D. Oeffinger M. Nucleolin and nucleophosmin: Nucleolar proteins with multiple functions in DNA repair. Biochem. Cell Biol. 2016 94 5 419 432 10.1139/bcb‑2016‑0068 27673355
    [Google Scholar]
  12. Tumban E. A current update on human papillomavirus-associated head and neck cancers. Viruses 2019 11 10 922 10.3390/v11100922 31600915
    [Google Scholar]
  13. Wolfson E. Solomon S. Schmukler E. Goldshmit Y. Pinkas-Kramarski R. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Cell Death Dis. 2018 9 2 47 10.1038/s41419‑017‑0067‑7 29352243
    [Google Scholar]
  14. Zhang J. Saba N.F. Chen G.Z. Shin D.M. Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Mol. Aspects Med. 2015 45 74 86 10.1016/j.mam.2015.07.001 26163475
    [Google Scholar]
  15. Li S. Hong X. Wei Z. Xie M. Li W. Liu G. Guo H. Yang J. Wei W. Zhang S. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation. Front. Microbiol. 2019 10 2483 10.3389/fmicb.2019.02483 31749782
    [Google Scholar]
  16. Du Z. Lovly C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 2018 17 1 58 10.1186/s12943‑018‑0782‑4
    [Google Scholar]
  17. Merino V.F. Yan Y. Ordonez A.A. Bullen C.K. Lee A. Saeki H. Ray K. Huang T. Jain S.K. Pomper M.G. Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. Antiviral Res. 2023 211 105550 10.1016/j.antiviral.2023.105550 36740097
    [Google Scholar]
  18. Thongchot S. Aksonnam K. Thuwajit P. Yenchitsomanus P.T. Thuwajit C. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). Int. J. Mol. Med. 2023 52 3 81 10.3892/ijmm.2023.5284 37477132
    [Google Scholar]
  19. Krsek A. Baticic L. Sotosek V. Braut T. The role of biomarkers in HPV-positive head and neck squamous cell carcinoma: Towards precision medicine. Diagnostics 2024 14 13 1448 10.3390/diagnostics14131448 39001338
    [Google Scholar]
  20. Tomaić V. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers 2016 8 10 95 10.3390/cancers8100095 27775564
    [Google Scholar]
  21. Tsai S.C.S. Huang J.Y. Lin C. Liaw Y.P. Lin F.C.F. The association between human papillomavirus infection and head and neck cancer. Medicine (Baltimore) 2019 98 7 e14436 10.1097/MD.0000000000014436 30762752
    [Google Scholar]
  22. Hübbers C.U. Akgül B. HPV and cancer of the oral cavity. Virulence 2015 6 3 244 248 10.1080/21505594.2014.999570 25654476
    [Google Scholar]
  23. Anderson G. Ebadi M. Vo K. Novak J. Govindarajan A. Amini A. An updated review on head and neck cancer treatment with radiation therapy. Cancers 2021 13 19 4912 10.3390/cancers13194912 34638398
    [Google Scholar]
  24. Tsimberidou A.M. Targeted therapy in cancer. Cancer Chemother. Pharmacol. 2015 76 6 1113 1132 10.1007/s00280‑015‑2861‑1 26391154
    [Google Scholar]
  25. Jain N. Zhu H. Khashab T. Ye Q. George B. Mathur R. Singh R.K. Berkova Z. Wise J.F. Braun F.K. Wang X. Patel K. Xu-Monette Z.Y. Courty J. Young K.H. Sehgal L. Samaniego F. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 2018 32 3 663 674 10.1038/leu.2017.215 28690315
    [Google Scholar]
  26. Kozani P.S. Kozani P.S. Malik M.T. AS1411-functionalized delivery nanosystems for targeted cancer therapy. Explor Med 2021 2 146 166 34723284
    [Google Scholar]
  27. Romano S. Fonseca N. Simões S. Gonçalves J. Moreira J.N. Nucleolin-based targeting strategies for cancer therapy: From targeted drug delivery to cytotoxic ligands. Drug Discov. Today 2019 24 10 1985 2001 10.1016/j.drudis.2019.06.018 31271738
    [Google Scholar]
  28. Van den Avont A. Sharma-Walia N. Anti-nucleolin aptamer AS1411: An advancing therapeutic. Front. Mol. Biosci. 2023 10 1217769 10.3389/fmolb.2023.1217769 37808518
    [Google Scholar]
  29. Dzhumashev D. Timpanaro A. Ali S. De Micheli A.J. Mamchaoui K. Cascone I. Rössler J. Bernasconi M. Quantum dot-based screening identifies F3 peptide and reveals cell surface nucleolin as a therapeutic target for rhabdomyosarcoma. Cancers 2022 14 20 5048 10.3390/cancers14205048 36291832
    [Google Scholar]
  30. Lopes-Nunes J. Oliveira P. Cruz C. G-Quadruplex-based drug delivery systems for cancer therapy. Pharmaceuticals 2021 14 7 671 10.3390/ph14070671 34358097
    [Google Scholar]
  31. Trinh T.L. Zhu G. Xiao X. Puszyk W. Sefah K. Wu Q. Tan W. Liu C. A synthetic aptamer-drug adduct for targeted liver cancer therapy. PLoS One 2015 10 11 e0136673 10.1371/journal.pone.0136673 26523833
    [Google Scholar]
  32. Iturriaga-Goyon E. Vivanco-Rojas O. Magaña-Guerrero F.S. Buentello-Volante B. Castro-Salas I. Aguayo-Flores J.E. Gracia-Mora I. Rivera-Huerta M. Sánchez-Bartés F. Garfias Y. AS1411 nucleolin-specific binding aptamers reduce pathological angiogenesis through inhibition of nucleolin phosphorylation. Int. J. Mol. Sci. 2021 22 23 13150 10.3390/ijms222313150 34884955
    [Google Scholar]
  33. Wang S. Yan X. Yang C. Naranmandura H. The landscape of nucleic-acid-based aptamers for treatment of hematologic malignancies: Challenges and future directions. Bioengineering 2022 9 11 635 10.3390/bioengineering9110635 36354547
    [Google Scholar]
  34. Li F. Lu J. Liu J. Liang C. Wang M. Wang L. Li D. Yao H. Zhang Q. Wen J. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun 2017 8 1390 10.1038/s41467‑017‑01565‑6
    [Google Scholar]
  35. Willmer T. Damerell V. Smyly S. Sims D. Du Toit M. Ncube S. Sinkala M. Govender D. Sturrock E. Blackburn J.M. Targeting the oncogenic TBX3: Nucleolin complex to treat multiple sarcoma subtypes. Am J Cancer Res. 2021 11 5680 5700 34873487
    [Google Scholar]
  36. Li S. Jiang Q. Liu S. Zhang Y. Tian Y. Song C. Wang J. Zou Y. Anderson G.J. Han J.Y. Chang Y. Liu Y. Zhang C. Chen L. Zhou G. Nie G. Yan H. Ding B. Zhao Y. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 2018 36 3 258 264 10.1038/nbt.4071 29431737
    [Google Scholar]
  37. Mastrangelo P. Norris M. Duan W. Barrett E. Moraes T. Hegele R. Targeting host cell surface nucleolin for RSV therapy: Challenges and opportunities. Vaccines 2017 5 3 27 10.3390/vaccines5030027 28925950
    [Google Scholar]
  38. Farahbakhsh Z. Zamani M.R. Rafienia M. Gulseren O. Mirzaei M. In silico activity of AS1411 aptamer against nucleolin of cancer cells. Iran. J. Blood Cancer 2020 12 95 100
    [Google Scholar]
  39. Papavassiliou K.A. Marinos G. Papavassiliou A.G. Combining STAT3-targeting agents with immune checkpoint inhibitors in NSCLC. Cancers 2023 15 2 386 10.3390/cancers15020386 36672335
    [Google Scholar]
  40. Zhang S. Gupta S. Fitzgerald T.J. Bogdanov A.A. Jr Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle - oligonucleotide nanoconstructs to head and neck cancer cells. Nanotheranostics 2018 2 1 1 11 10.7150/ntno.22335 29291159
    [Google Scholar]
  41. Brignole C. Bensa V. Fonseca N.A. Del Zotto G. Bruno S. Cruz A.F. Malaguti F. Carlini B. Morandi F. Calarco E. Perri P. Moura V. Emionite L. Cilli M. De Leonardis F. Tondo A. Amoroso L. Conte M. Garaventa A. Sementa A.R. Corrias M.V. Ponzoni M. Moreira J.N. Pastorino F. Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. J. Exp. Clin. Cancer Res. 2021 40 1 180 10.1186/s13046‑021‑01993‑9 34078433
    [Google Scholar]
  42. Allegra E. Trapasso Cancer stem cells in head and neck cancer. OncoTargets Ther. 2012 10 3 375 10.2147/OTT.S38694 34552815
    [Google Scholar]
  43. Carvalho L.S. Gonçalves N. Fonseca N.A. Moreira J.N. Cancer stem cells and nucleolin as drivers of carcinogenesis. Pharmaceuticals 2021 14 1 60 10.3390/ph14010060 33451077
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096370250250513115130
Loading
Nucleolin as a Crucial Player in Head and Neck Cancer: Diagnostic and Therapeutic Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/0115680096370250250513115130
/content/journals/ccdt/10.2174/0115680096370250250513115130
/content/journals/ccdt/10.2174/0115680096370250250513115130
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: TCGA ; targeted therapy ; head and neck cancer ; HPV ; Nucleolin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test